Adagene Spon Ads Each Rep 1.25 Ord Shs (ADAG) Stock
Small cap biotech company engineering antibodies for cancer. Here's the price, business snapshot, and what's worth knowing about Adagene Spon Ads Each Rep 1.25 Ord Shs in October 2026.
Adagene Inc-ADR (ADAG) is a small-cap, clinical-stage biotechnology company focused on antibody discovery and engineering to develop immuno‑oncology and immune-modulating therapies. Listed as an American Depositary Receipt, it combines research platforms with collaborations to advance therapeutic candidates from preclinical studies into clinical trials. With a market capitalisation around $89.08 million, Adagene is at an early development stage: its value is driven mainly by pipeline progress, partnership deals and trial data rather than steady revenues. Investing in clinical-stage biotech carries heightened risks — programmes can fail, dilutive financing may be needed and share price volatility is common. For investors, it’s useful to monitor trial milestones, cash runway, partnership announcements and regulatory updates. This summary is for general educational purposes only and is not personalised investment advice; investors should consider their risk tolerance and consult a financial professional before making investment decisions.
Adagene Spon Ads Each Rep 1.25 Ord Shs (ADAG) Stock Forecast
Analyst price target, next 12 months
$9.08
+228.8% vs today's $2.76
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Adagene Spon Ads Each Rep 1.25 Ord Shs have a consensus 12-month target of $9.08, above the current price of $2.76.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 6 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Adagene's stock with a target price of $9.07, indicating strong potential growth.
Financial Health
Adagene has modest revenue and cash flow, indicating some financial stability but limited growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Milestones Matter
Clinical trial readouts, INDs and partnership deals can drive revaluation, though outcomes are uncertain and timing may be unpredictable.
Collaborations and Partners
Licensing and alliances can de‑risk programmes and provide funding, but agreements vary and may affect long‑term upside.
Small‑Cap Volatility
With a sub‑$100M market cap, shares can swing sharply on news; this may suit risk‑tolerant investors but carries higher downside.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
